Overview
- A pooled analysis published in JAMA and presented at the Alzheimer’s Association conference on Wednesday used data from 2,684 symptom-free older adults followed between 2004 and 2025 to assess p‑tau217 blood levels.
- Participants with very high p‑tau217 had an estimated 38% chance of developing cognitive impairment within five years and a 78% chance within ten years compared with much lower risk for those with low levels.
- Study authors and independent commentators warned the test lacks the precision for individual prognoses because only a subset had full 10‑year follow up and other age‑related conditions can affect results.
- Investigators say the most immediate, practical use is to enrich preventive clinical trials by selecting people at higher biological risk rather than to screen healthy people in routine care.
- Clinicians and experts advise continuing proven brain‑health actions such as exercise, healthy diet, good sleep, social and mental activity, and to see a doctor for persistent memory change while tests and therapies are further validated.